

**12th JOINT MEETING  
OF  
BRITISH ENDOCRINE SOCIETIES**

**29 March - 1 April 1993  
Liverpool**

*These abstracts are published in good faith exactly as received from the submitting authors. The opinions and views within are those of the submitting authors and have not been verified by the Societies, who accept no scientific responsibility for the statements made or for their content. It is not possible to guarantee that the abstracts printed in this Supplement will be presented at the Meeting.*

© 1993 Journal of Endocrinology Ltd

**BRITISH ENDOCRINE SOCIETIES**

**Benefactors**

Clinical Endocrinology Trust  
Farmitalia Carlo Erba  
Ferring Pharmaceuticals  
Kabi Pharmacia  
Novo Nordisk  
Sandoz Pharmaceuticals  
Serono Laboratories  
ZENECA Pharma

## CONTENTS

### PLENARY LECTURERS' BIOGRAPHICAL NOTES

#### PLENARY LECTURES

Society for Endocrinology Medal Lecture	S1
Society for Endocrinology Dale Medal Lecture	S2
Society for Endocrinology Transatlantic Medal Lecture	S3
Thyroid Club Pitt-Rivers Lecture	S4
Clinical Endocrinology Trust Lecture	S5
Royal Society of Medicine Lecture	S6

#### SYMPOSIA

Steroids and the brain	S7-S10
Paracrinology of early pregnancy	S11-S14
Angiogenesis as an endocrine response	S15-S18
Aetiology of endocrine tumours	S19-S22
Renin-angiotensin-aldosterone axis	S23-S26
Endocrine autoimmunity	S27-S31

#### CLINICAL MANAGEMENT WORKSHOPS

Endocrine management of breast cancer	S32-S33
Thyroid eye disease	S34-S35
Secondary osteoporosis	S36-S38

#### METHODS UPDATES

Non-isotopic in-situ hybridization	S39-S40
Gonadotrophin bioassay versus immunoassay	S41

#### RESEARCH COLLOQUIA

Steroid action	S42, RC1-RC4
Intracellular signalling	S43, RC5-RC8

#### ORAL COMMUNICATIONS

Growth	OC1-OC5
Reproduction	OC6-OC11
Endocrine pathology	OC12-OC17
Thyroid	OC18-OC28
Neuroendocrinology	OC29-OC33
Steroidogenesis	OC34-OC38

#### POSTER PRESENTATIONS

Adrenal	P1-P26
Bone and calcium	P27-P40
Diabetes	P41-P50
Endocrine pathology	P51-P67
Growth	P68-P89
Methodology	P90-P98

Neuroendocrinology  
Pituitary  
Regulatory peptides  
Reproduction  
Thyroid

P99-P121  
P122-P152  
P153-P165  
P166-P207  
P208-P237

**INDEX OF FIRST AUTHORS**

P183 THE EFFECTS OF ICI 182,780, A PURE ANTI-OESTROGEN, ON REPRODUCTIVE ENDOCRINOLOGY IN NORMAL PRE-MENOPAUSAL WOMEN

E.J. Thomas<sup>1</sup>, N.M. Thomas<sup>1</sup>, P.L. Walton<sup>2</sup> and M. Dowsett<sup>3</sup>

<sup>1</sup>Obstetrics and Gynaecology, Southampton, <sup>2</sup>ICI Pharmaceuticals, Alderley Edge and

<sup>3</sup>Biochemistry, Royal Marsden Hospital

ICI 182,780 has been found in vitro and in animal models to exert a pure anti-oestrogenic action with no agonist activity. 19 pre-menopausal women were prescribed 182,780, 12 mg intramuscularly, daily for 7 seven days prior to hysterectomy starting between day 5 to day 9 of the menstrual cycle, for benign gynaecological disease. 11 controls were also recruited. No significant adverse events were reported in either group. 3 women in the treatment group were withdrawn because of endocrine abnormalities or because they were in the luteal phase at the beginning of treatment. 12 of the 16 remaining treated women showed a consistent response to ICI 182,780 characterised by no increase in the plasma concentration of LH and FSH, no LH surge, continuing follicular growth ultrasonically, increasing plasma oestradiol concentrations, no increase in endometrial thickness and no ultrasonic evidence of ovarian hyperstimulation. The remaining 4 women showed an increase in endometrial thickness in parallel with an increase in plasma oestradiol concentration. Overall plasma oestradiol concentrations were significantly higher in the treated group compared with control group over the sampling interval. Pharmacodynamic data are being analyzed. Overall the results suggest that in a majority of pre-menopausal women ICI 182,780, 12 mg daily for 7 days does not stimulate gonadotrophin secretion and will suppress endometrial growth in spite of continuing oestradiol stimulation. The absence of adverse events or of evidence of ovarian hyperstimulation suggests that this compound may be able to be used for the treatment of oestrogen dependent diseases in pre-menopausal women.

P184 COMPARISONS OF THE BIOACTIVITY OF FEMALE RAT PITUITARY AND PLASMA LH

A.J. Leigh, T. Shakil\*, S.A. Fickling+ and C.A. Wilson. Departments Obstetrics & Gynaecology, Physiology\* and Cellular & Molecular Science+, St. George's Hospital Medical School, London SW17 ORE.

Pituitary and plasma LH possess different physico-chemical characteristics (1). We have now compared their bioactivities "in vitro", investigating their ability to stimulate the production of testosterone, progesterone and tissue plasminogen activator (tPA).

Pituitaries (n=9) and plasma (n=7) were collected on proestrus, the former were homogenised in buffer and the supernatant diluted 1:500. All samples were assayed by radioimmunoassay (RIA; NIH-RP3 standard) and the mouse Leydig cell bioassay. Samples were incubated for 48 hours with cultured granulosa cells isolated from rat ovarian follicles ( $\geq 400 \mu\text{m}$  diameter) and then the culture medium was assayed for progesterone by RIA. Samples were also incubated for 48 hours with SV40 transected human umbilical vein endothelial cells (SGHEC7) and the incubate assayed for total tPA by Elisa.

Results standardised to the concentration of steroid or tPA produced per ng of immunogenic LH showed that the ratio of plasma to pituitary activity was 4.1:1 for testosterone production; 3.8:1 for progesterone production, while for tPA, plasma LH produced  $107 \pm 16.5 \text{ ng/ml/ng LH}$  (n=7) but pituitary LH applied to the cells at  $4.9 \pm 0.2 \text{ ng}$  (n=9) was inactive.

These findings indicate that on release of LH from the pituitary gland into the circulation, there is a 4-fold increase in steroidogenic activity of LH, and also an increase in its ability to produce tPA

1. Leigh, A.J., Chapman, A.J. & Wilson, C.A. J. Reprod. Fertil. Abstract Series 3. No 115 (1989).